(Q52102663)

22 April 2018

title

Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. (English)

1 reference

22 April 2018

1 reference

Thomas Müller

1

1 reference

22 April 2018

Margareta Meisel

series ordinal

2

1 reference

22 April 2018

Herrmann Russ

series ordinal

3

1 reference

22 April 2018

Horst Przuntek

series ordinal

4

1 reference

22 April 2018

publication date

1 September 2003

1 reference

22 April 2018

Journal of the Neurological Sciences

published in

1 reference

22 April 2018

volume

213

1 reference

22 April 2018

issue

1-2

1 reference

22 April 2018

page(s)

61-65

1 reference

22 April 2018

Measurements of visual evoked potentials in Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Proposals for scoring and assessing the 100-Hue test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Decreased color discrimination and contrast sensitivity in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Distorted color discrimination in 'de novo' parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Colour vision abnormalities and movement time in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Distorted colour discrimination in Parkinson's disease is related to severity of the disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Quantification of the dopaminergic response in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Test-retest reliability of the Purdue Pegboard Test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

L-Dopa improves colour vision in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Effects of apomorphine on visual functions in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Levodopa improves spatial contrast sensitivity in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Effect of practice on performance of a skilled motor task in patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Predominant affection of the blue cone pathway in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

The dopaminergic amacrine cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Connexions between retinal neurons with identified neurotransmitters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Cognitive deficits in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Internal versus external cues and the control of attention in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Attentional functions in multiple system atrophy and Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Quantitative assessment of bradykinesia in patients with Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

The neurobiological basis of movement initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Correlation between tapping and inserting of pegs in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2803%2900150-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(03)00150-3

1 reference

22 April 2018

1 reference

22 April 2018